Annual report pursuant to Section 13 and 15(d)

SEGMENT REPORTING (Tables)

v3.20.4
SEGMENT REPORTING (Tables)
12 Months Ended
Dec. 31, 2020
Segment Reporting [Abstract]  
Schedule of Segment Reporting Information, by Segment [Table Text Block]

Information concerning the operations of the Company’s reportable segments is as follows:

 

   

BioSig

Technologies, Inc

   

ViralClear

Pharmaceuticals, Inc.

   

NeuroClear

Technologies,

Inc.

   

Total

 

Operating expenses:

                               

Research and development

  $ 4,399,182     $ 13,705,050     $ 31,630     $ 18,135,862  

General and administrative

    26,264,331       14,680,519       9,403       40,954,253  

Depreciation and amortization

    91,818       1,429       286       93,533  

Total operating expenses

    30,755,331       28,386,998       41,319       59,183,648  
                                 

Loss from Operations

    (30,755,331

)

    (28,386,998

)

    (41,319

)

    (59,183,648

)

                                 

Other income:

                               

Interest income and other income, net

    29,480       14,855       -       44,335  
                                 

Net loss

  $ (30,725,851

)

  $ (28,372,143

)

  $ (41,319

)

  $ (59,139,313

)

 

   

BioSig

Technologies, Inc

   

ViralClear

Pharmaceuticals, Inc.

   

NeuroClear

Technologies,

Inc.

   

Total

 

Cash

  $ 22,684,516     $ 5,583,513     $ -     $ 28,268,029  

Inventory

    768,319       -       -       768,319  

Other current assets

    270,623       29,928       -       300,551  

Total operating assets

    23,723,458       5,613,441       -       29,336,899  
                                 

Property and equipment, net

    279,985       8,575       -       288,560  

Right-to-use assets, net 

    306,484       -       -       306,484  

Other assets

    453,494       -       -       453,494  
                                 

Total assets

  $ 24,763,421     $ 5,622,016     $ -     $ 30,385,437